Cytochrome P4502C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient

被引：28
|
作者：
Stempak, D
Bukaveckas, BL
Linder, M
Koren, G
Baruchel, S
机构：
[1] Hosp Sick Children, Div Hematol Oncol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
[2] Hosp Sick Children, Div Clin Pharmacol & Toxicol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
[3] Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40292 USA
[4] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
[5] Hosp Sick Children, Div Hematol Oncol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 78卷 / 03期
关键词：
D O I：
10.1016/j.clpt.2005.06.005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：309 / 310
页数：2
相关论文
共 50 条
  • [41] Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Demmark
    Pedersen, RS
    Verstuyft, C
    Becquemont, L
    Jaillon, P
    Brosen, K
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 94 (03) : 151 - 152
  • [42] Frequency of cytochrome P4502C9 allelic variants in the Chinese and French populations
    Yang, JQ
    Morin, S
    Verstuyft, C
    Fan, LA
    Zhang, Y
    Di Xu, C
    Barbu, V
    Jaillon, P
    Becquemont, L
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (03) : 373 - 376
  • [43] Comparison of cytochrome P4502C9 genotyping methods and implications for the clinical laboratory
    Aquilante, CL
    Lobmeyer, MT
    Langaee, TY
    Johnson, JA
    PHARMACOTHERAPY, 2004, 24 (06): : 720 - 726
  • [44] Enantiospecific effects of cytochrome P4502C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2
    Kirchheiner, J
    Meineke, I
    Freytag, G
    Meisel, C
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (01) : 62 - 75
  • [45] Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein
    Yasar, Ü
    Annas, A
    Svensson, JO
    Lazorova, L
    Artursson, P
    Al-Shurbaji, A
    XENOBIOTICA, 2005, 35 (08) : 785 - 796
  • [46] Modeling and synthesis of novel tight-binding inhibitors of cytochrome P4502C9
    Peng, Chi-Chi
    Rushmore, Tom
    Crouch, Gregory J.
    Jones, Jeffrey P.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (07) : 4064 - 4074
  • [47] Metabolites of cytochrome P4502C9 are not essential for the regulation of coronary vasomotor tone in swine
    Merkus, D
    Sorop, O
    Houweling, B
    Duncker, DJ
    FASEB JOURNAL, 2006, 20 (05): : A1399 - A1399
  • [48] Cytochrome P4502C9 plays an important role in the regulation of exercise hyperemia in humans
    Hillig, T
    Krustrup, P
    Fleming, I
    Osada, T
    Saltin, B
    Hellsten, Y
    FASEB JOURNAL, 2002, 16 (05): : A1140 - A1140
  • [49] Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P4502C9
    Gannett, PM
    Kabulski, J
    Perez, FA
    Liu, ZY
    Lederman, D
    Locuson, CW
    Ayscue, RR
    Thomsen, NM
    Tracy, TS
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (26) : 8374 - 8375
  • [50] Cytochrome P4502C9 induces cycloxygenase-2 expression in endothelial cells
    Michaelis, UR
    Fisslthaler, B
    Fleming, I
    Busse, R
    EUROPEAN HEART JOURNAL, 2003, 24 : 13 - 13
12345